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CLSI zone size and Minimum Inhibitory Concentration interpretive
criteria were examined.
Results: One hundred forty-nine patients with brucellosis were
enrolled in this study. Culture of clinical samples were pos-
itive in 38.3%, of which, 91.2% were associated with positive
serological test. No signiﬁcant associations were found between
serological tests and culture method. All clinical isolates were
sensitive to doxycycline, streptomycin, gentamicin, ciproﬂoxacin
and moxiﬂoxacin, but intermediate sensitivity to rifampin and
trimethoprim-sulfamethoxazole were found in 35.08% and 3.5% of
isolates, respectively.
Conclusion: Because of the high frequency of intermediate sen-
sitivity to rifampin among brucella isolates, this drug should be
prescribed with caution. We recommend restricting the use of
rifampin for treatment of brucellosis except as an alternative drug
for special situations.
http://dx.doi.org/10.1016/j.ijid.2016.02.244
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In-vitro activity of Fosfomycin against clinical
isolates of carbapenem resistant Acinetobacter
baumannii complex and Pseudomonas
aeruginosa at a South African academic hospital
A.A. Hoosen ∗, K. Baba
University of the Free State, Bloemfontein, South
Africa
Background: Carbapenem resistant Acinetobacter baumannii
complex and Pseudomonas aeruginosa are a major health problem
in our hospital, most of them being multidrug resistant strains
which are difﬁcult to treat with the current available antimicrobial
agents. This studywasundertaken toevaluate the in-vitroactivityof
fosfomycin as alternative treatment against carbapenem resistant
isolates.
Methods & Materials: Consecutive clinical isolates of car-
bapenem resistant Acinetobacter baumannii complex and Pseu-
domonas aeruginosa were collected over a 6 month study
period. Species identiﬁcation and antimicrobial susceptibility test-
ing was performed using Vitek-2 colorimetric compact systems
(BIOMERIUX, France). Fosfomycin testingwas initially done by disk
diffusion, thereafter the gradient diffusion method using the Etest
strips (LIOFILCHEM, Italy) was done for the veriﬁcation of themini-
mum inhibitory concentrations. Themodiﬁed Hodge test was done
to detect the presence of carbapenemases.
Results: A total of 133 carbapenems resistant clinical isolates
(72 (54.1%) Acinetobacter baumannii and 61 (45.9) Pseudomonas
aeruginosa), were collected from 125 patients. The majority of
patients were males between 30-60yrs and 72 (57.6%) were in the
ICUs, while 53 (42.4%) were in other wards. The specimens were
from Endo-Tracheal Aspirates (ETA) 80 (60.1%), 17 (12.8%) from
blood culture, 16 (12%) from wound swabs, tissues and effusions,
11 (8.3%) from CVP tips and 9 (6.8%) from urine. All isolates were
susceptible to fosfomycin in addition to colistin.
ANTIBIOTIC MIC range
ug/ml
Susceptible Intermediate Resistant
Colistin ≤ 2- ≥ 4 100% – –
Fosfomycin gradient
diffusion
≤ 64 - ≥
256
100% – –
Fosfomycin disk
diffusion
≤ 12 - ≥ 16 44.5% 47.2% 8.3%
Conclusion: In conclusion, treatment options for infections due
to carbapenem and multi-drugs resistant Acinetobacter bauman-
nii and Pseudomonas aeruginosa organisms are limited, therefore
fosfomycin may be considered as a therapeutic option for these
organisms.
http://dx.doi.org/10.1016/j.ijid.2016.02.245
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pncA mutations in mycobacterium tuberculosis
is a strong predictor of poor treatment outcome
in the therapy of multidrug resistant
tuberculosis
D. Li, Y. Hu ∗
Fudan University, Shanghai, China
Background: Despite the widely accepted association between
Pyrazinamide (PZA) resistance and mutations in pncA and rpsA
gene, it remainedunknownabout the clinical value of PZA genotypic
drug susceptibility testing(DST) for multidrug resistant tuberculosis
(MDR-TB) treatment, especially in the resource-limited area,where
the PZA phenotypic DST is difﬁcult to be implemented. Thus this
study was aimed at evaluating the role of PZA genotypic DST in
predicting poor treatment outcome in a MDR-TB treatment cohort.
Methods & Materials: This is a cohort study of 74 MDR-
TB patients who were identiﬁed and admitted to two Chinese
designated hospitals in 2010–2011. Demographic and clinical
information including treatment outcomes (sputum smear conver-
sion and treatment success) were retrieved from medical records.
Susceptibility to PZA and other 2nd line drugs were tested with the
MGIT 960 PZA kit.Mutations in pncA and rpsA geneswere identiﬁed
by DNA sequencing.
Results: Among 74 MDR-TB cases, 27 (36.5%) were pre-XDR TB
and 5(6.8%) were XDR-TB. 44.6% (33/74) had PZA resistance with
84.8% (28/33) mutations in pncA gene and 3.0% (3.0%) mutation
in rpsA gene. When comparing the treatment success reﬂected by
smear negativity after two months of standardized MDR-TB ther-
apy and a successful ﬁnal outcome it is clearly seen that a pncA
mutation predicted a less favorable response to treatment. A total
of 21 (75%) of the patients having a strain with such a mutation
were still smear positive after two months compared to 24 (53.3%)
in the groupwith strains showing the pncAwt sequence(OR: 0.511;
95%CI: 0.262–1.084). Similarly resultswere seen for ﬁnal treatment
success (registered after 24 months), were 9/26 cases and 29/41
cases respectively responded successfully based onWHOguideline
(OR: 0.107; 95%CI: 0.015–0.773).
